- Priti Radhakrishnan: Prescription drug prices are soaring; for example, a $1,000-per-pill hepatitis C drug
- She argues that opposing drug company patent applications is one route to lower prices
Priti Radhakrishnan is co-founder and director of the Initiative for Medicines, Access & Knowledge (I-MAK), which is a U.S.-based nonprofit group of scientists and lawyers working globally to get people lifesaving medicine. Prior to founding I-MAK, Radhakrishnan worked as a health attorney in the U.S., Switzerland and India. The opinions expressed in this commentary are hers.
(CNN)Prescription drug prices are soaring, as exemplified by pharmaceutical giant Gilead's $1,000-per-pill hepatitis C drug, Sovaldi. High prices for drugs that treat deadly diseases are creating barriers for patients, burdening governments and leading to rationing and denial of lifesaving treatments around the world.